Bright Minds Biosciences Inc(DRUG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 7:30 PM ET (Korea 9/15 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.08 | Insider Own | 23.39% | Shs Outstand | 9.9M | Perf Week | -2.73% |
| Market Cap | 0.63B | Forward P/E | - | EPS next Y | -141.78% | Insider Trans | -4.52% | Shs Float | 7.6M | Perf Month | -18.74% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | -1.06 | Inst Own | 83.47% | Short Float | 11.82% | Perf Quarter | 3.99% |
| Income | -0.02B | P/S | - | EPS this Y | -98.32% | Inst Trans | 2.9% | Short Ratio | 4.09 | Perf Half Y | -11.97% |
| Sales | 0.00B | P/B | 2.88 | EPS next 5Y | - | ROA | -13.8% | Short Interest | 0.89M | Perf YTD | -18.79% |
| Book/sh | 21.99 | P/C | 2.88 | EPS past 3/5Y | 35.51% -35.46% | ROE | -13.93% | 52W High | -48.78% ($123.75) | Perf Year | 30.01% |
| Cash/sh | 22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -8.18% | 52W Low | 43.23% ($44.25) | Perf 3Y | 3745.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -120.28% | Gross Margin | - | Volatility(W/M) | 4.47% 4.83% | Perf 5Y | 132.16% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 121.97 | EPS Q/Q | 67.03% | Profit Margin | - | RSI (14) | 31.78 | Recom | 1.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 121.97 | Sales Q/Q | - | SMA20 | -12.89% ($72.76) | Beta | -5.12 | Target Price | $149.56 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/17 | SMA50 | -14.52% ($74.15) | Rel Volume | 0.19 | Prev Close | $63.18 |
| Employees | 25 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 85.85% - | SMA200 | -18.76% ($78.02) | Avg Volume(3M) | 0.22M | Price | $63.38 |
| IPO | 2021/3/22 | Option/Short | Yes/Yes | Trades | 1667 | Volume | 42,154 | Change | 0.32% |
Company
DRUG is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 Bright Minds Biosciences (ticker DRUG) is a clinical-stage biotech company developing next-generation therapies for neurological and psychiatric disorders that target serotonin receptors. Its core pipeline includes a serotonin-agonist candidate aimed at drug-resistant epilepsy, and through selective receptor modulation technology, the company is pursuing novel drug candidates designed to overcome the limitations of existing treatments.
Over the past 1 year, on the lower side
49% below its 1-year high.
DRUG has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -98.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +3745.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 83.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PSIL 0.04%
IBRN 0.01%
VFMO 0.00%
IWC 0.00%
CAS 0.00%It ranks #4 in the industry
Based on market cap of $625M.
DRUG $625M PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is DRUG?
DRUG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DRUG?
The market cap of DRUG is approximately $625M, ranking 3,031 within its sector.
What is the 52-week high and low for DRUG?
DRUG has recorded a 52-week high of $123.75 and a low of $44.25.
